JP2024539193A5 - - Google Patents
Info
- Publication number
- JP2024539193A5 JP2024539193A5 JP2024523783A JP2024523783A JP2024539193A5 JP 2024539193 A5 JP2024539193 A5 JP 2024539193A5 JP 2024523783 A JP2024523783 A JP 2024523783A JP 2024523783 A JP2024523783 A JP 2024523783A JP 2024539193 A5 JP2024539193 A5 JP 2024539193A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai agent
- nucleotide
- agent according
- modified
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163270849P | 2021-10-22 | 2021-10-22 | |
| US63/270,849 | 2021-10-22 | ||
| US202263308289P | 2022-02-09 | 2022-02-09 | |
| US63/308,289 | 2022-02-09 | ||
| US202263345654P | 2022-05-25 | 2022-05-25 | |
| US63/345,654 | 2022-05-25 | ||
| PCT/US2022/078498 WO2023070082A2 (en) | 2021-10-22 | 2022-10-21 | Rnai agents for inhibiting expression of matrix metalloproteinase 7(mmp7), compositions thereof, and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539193A JP2024539193A (ja) | 2024-10-28 |
| JP2024539193A5 true JP2024539193A5 (https=) | 2025-10-28 |
Family
ID=86059695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523783A Pending JP2024539193A (ja) | 2021-10-22 | 2022-10-21 | マトリックスメタロプロテイナーゼ７（ＭＭＰ７）の発現を抑制するためのＲＮＡｉ剤、その組成物、及び使用の方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230265437A1 (https=) |
| EP (1) | EP4419689A2 (https=) |
| JP (1) | JP2024539193A (https=) |
| KR (1) | KR20240099296A (https=) |
| AU (1) | AU2022368927A1 (https=) |
| CA (1) | CA3235224A1 (https=) |
| CL (1) | CL2024001175A1 (https=) |
| CO (1) | CO2024005110A2 (https=) |
| IL (1) | IL312239A (https=) |
| MX (1) | MX2024004912A (https=) |
| PE (1) | PE20241185A1 (https=) |
| TW (1) | TW202334416A (https=) |
| WO (1) | WO2023070082A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202503060A (zh) * | 2023-06-13 | 2025-01-16 | 大陸商上海拓界生物醫藥科技有限公司 | 靶向ＭＭＰ７的ｓｉＲＮＡ、ｓｉＲＮＡ綴合物及其醫藥用途 |
| CN121693569A (zh) | 2023-07-28 | 2026-03-17 | 长春金赛药业有限责任公司 | siRNA及其组合物 |
| CN120309596A (zh) * | 2024-01-15 | 2025-07-15 | 武汉人福创新药物研发中心有限公司 | 靶向αvβ6的化合物及其用途 |
| WO2025228156A1 (zh) * | 2024-04-30 | 2025-11-06 | 北京炫景瑞医药科技有限公司 | 肾靶向的双链寡核苷酸缀合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| US20050118625A1 (en) * | 2003-10-02 | 2005-06-02 | Mounts William M. | Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases |
| WO2006092795A2 (en) * | 2005-03-01 | 2006-09-08 | Qbi Enterprises Ltd. | Oligoribonucleotides and methods of use thereof for treatment of ocular scarring and other fibrotic conditions |
| WO2019089765A1 (en) * | 2017-11-01 | 2019-05-09 | Arrowhead Pharmcaceuticals, Inc. | Integrin ligands and uses thereof |
| US12372530B2 (en) * | 2017-11-15 | 2025-07-29 | Beth Israel Deaconess Medical Center, Inc. | Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis |
| CN116783294A (zh) * | 2020-09-11 | 2023-09-19 | 箭头药业股份有限公司 | 整联蛋白靶向配体及其用途 |
-
2022
- 2022-10-21 US US18/048,577 patent/US20230265437A1/en active Pending
- 2022-10-21 CA CA3235224A patent/CA3235224A1/en active Pending
- 2022-10-21 IL IL312239A patent/IL312239A/en unknown
- 2022-10-21 WO PCT/US2022/078498 patent/WO2023070082A2/en not_active Ceased
- 2022-10-21 KR KR1020247016352A patent/KR20240099296A/ko active Pending
- 2022-10-21 EP EP22884722.4A patent/EP4419689A2/en active Pending
- 2022-10-21 AU AU2022368927A patent/AU2022368927A1/en active Pending
- 2022-10-21 MX MX2024004912A patent/MX2024004912A/es unknown
- 2022-10-21 TW TW111140110A patent/TW202334416A/zh unknown
- 2022-10-21 JP JP2024523783A patent/JP2024539193A/ja active Pending
- 2022-10-21 PE PE2024000898A patent/PE20241185A1/es unknown
-
2024
- 2024-04-15 CL CL2024001175A patent/CL2024001175A1/es unknown
- 2024-04-23 CO CONC2024/0005110A patent/CO2024005110A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024539193A5 (https=) | ||
| JP2025185070A5 (https=) | ||
| JP2022501040A5 (https=) | ||
| JP2024516096A5 (https=) | ||
| JP2020526192A5 (https=) | ||
| JP2023123756A5 (https=) | ||
| JP2025128190A5 (https=) | ||
| JP2023519246A5 (https=) | ||
| JP7697889B2 (ja) | アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法 | |
| TW201803989A (zh) | 拮抗ｂ型肝炎病毒之組成物和藥劑及彼等之用途 | |
| JP2016523863A5 (https=) | ||
| CN1247473A (zh) | 治疗与呼吸失调和肺部炎症相关的疾病和症状的药剂和方法 | |
| JP2023536999A (ja) | Ｂ型肝炎患者のオリゴヌクレオチド処置 | |
| CN107073114A (zh) | 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘 | |
| JP2010500291A5 (https=) | ||
| JP2024515880A5 (https=) | ||
| JP2024520522A5 (https=) | ||
| JP2015532100A (ja) | アンフィレギュリンに特異的な二重鎖オリゴｒｎａ、そのような二重鎖オリゴｒｎａを含む二重鎖オリゴｒｎａの構造体及びこれを含む呼吸器疾患の予防または治療用の組成物 | |
| WO2022056897A1 (zh) | 白细胞介素37与干扰素联用在治疗病毒感染中的应用 | |
| JP2023541170A (ja) | Ｚ－ａａｔタンパク質のレベルを低下させる方法 | |
| JP7514563B2 (ja) | オルガノイドおよび抗炎症剤を含む炎症性腸疾患の予防または治療用薬学組成物 | |
| KR20230088810A (ko) | 마이크로rna-29 화합물, 조성물 및 요법에서의 용도 | |
| Wang et al. | Mucosal and transdermal delivery strategies for mRNA: Transforming the clinical applications | |
| JP6021952B2 (ja) | 慢性閉塞性肺疾患の治療法 | |
| US20260103712A1 (en) | Anti-fibrotic microrna composition |